IMMUNEONCO BIOPHARMA
ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early stage biopharmaceutical company dedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells.
IMMUNEONCO BIOPHARMA
Industry:
Biopharma Biotechnology Health Care
Founded:
2015-06-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.immuneonco.com
Total Employee:
11+
Status:
Active
Contact:
+86-21-58356573
Email Addresses:
[email protected]
Total Funding:
147.21 M USD
Technology used in webpage:
SPF China Telecom Alibaba Cloud MailBox
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
Current Employees Featured
Founder
Investors List
Milestone
Milestone investment in Series C - ImmuneOnco Biopharma
Sunshine Insurance Group
Sunshine Insurance Group investment in Series C - ImmuneOnco Biopharma
CCB Trust
CCB Trust investment in Series C - ImmuneOnco Biopharma
Lilly Asia Ventures
Lilly Asia Ventures investment in Series C - ImmuneOnco Biopharma
Founder H Fund
Founder H Fund investment in Series C - ImmuneOnco Biopharma
CDF-Capital
CDF-Capital investment in Series C - ImmuneOnco Biopharma
CASH Capital
CASH Capital investment in Series C - ImmuneOnco Biopharma
Zhangke Lingyi Investment
Zhangke Lingyi Investment investment in Series C - ImmuneOnco Biopharma
Shanghai International Group (SIG)
Shanghai International Group (SIG) investment in Series C - ImmuneOnco Biopharma
LYFE Capital
LYFE Capital investment in Series C - ImmuneOnco Biopharma
Official Site Inspections
http://www.immuneonco.com Semrush global rank: 7.79 M Semrush visits lastest month: 437
- Host name: 121.199.6.220
- IP address: 121.199.6.220
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "ImmuneOnco Biopharma"
ImmuneOnco Biopharma - Crunchbase Company โฆ
ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early stage biopharmaceutical company dedicated to the development and commercialization of novel cancer immunotherapy โฆSee details»
ImmuneOnco - ๅฎๆๆ็ง่ฑๆ-ๅฎๆๆ็ง่ฑๆ
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was established in the PRC in June 2015. ImmuneOnco is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. ImmuneOnco is one of the โฆSee details»
ImmuneOnco - Products, Competitors, Financials, Employees, โฆ
ImmuneOnco is also accelerating development of IMM2510/SYN-2510 in front-line TNBC with initial Phase 1b/2 chemotherapy combination studies targeted to begin in early 2025. In the โฆSee details»
ImmuneOnco Biopharma - Funding, Financials, Valuation & Investors
ImmuneOnco is a tumor immunotherapy product developer engaged in the development and research of tumor immunotherapy products. Search Crunchbase. ... How much funding has โฆSee details»
ImmuneOnco Biopharma Co., Ltd - VentureRadar
ImmuneOnco Biopharmaceuticals is a pioneering biotechnology company focused on developing first-in-class immuno-oncology therapies. By harnessing both the innate and adaptive immune โฆSee details»
ImmuneOnco Biopharmaceuticals โ HK$319 Million โฆ
Hong Kong โ September 5, 2023 โ Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million global โฆSee details»
ImmuneOnco Biopharma - Craft
ImmuneOnco Biopharma (ๅฎๆๆ็ง็็ฉๅป่ฏๆๆฏ) is a biopharmaceutical company dedicated to the development and commercialization of cancer immunotherapy products. It aims to reverse โฆSee details»
ImmuneOnco and Instil Bio Announce License and Collaboration โฆ
Aug 1, 2024 ImmuneOnco is a clinical-stage biotech company focused on discovery and development of biologics to treat cancers and other diseases. With 10+ assets all originated in โฆSee details»
ImmuneOnco Biopharma - Contacts, Employees, Board Members โฆ
Organization. ImmuneOnco Biopharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. โฆSee details»
ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO โฆ
Mar 31, 2023 ImmuneOnco has raised funds six times, taking its valuation from 71.43 million yuan in 2015 to $830 million after its latest round in January 2022, an increase of more than โฆSee details»
Instil Bio and ImmuneOnco Announce License and Collaboration โฆ
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, โInstilโ) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, โฆSee details»
Immuneonco bags $25M in series B for CD47 antibodies โฆ
Oct 23, 2020 HONG KONG โ Shanghai, China-based Immuneonco Biopharmaceuticals Co. Ltd. bagged $25 million in series B financing in October. โThe financing was led by Lilly Asia โฆSee details»
ImmuneOnco Sells Rights for Two Assets to Instil in $2 Billion Deal
Aug 2, 2024 ImmuneOnco will receive an upfront and near-term payments of $50 million and up to more than $2 billion in milestones, plus royalties. Instil will have rights to ImmuneOncoโs โฆSee details»
Instil Bio and ImmuneOnco Announce License and ... - Morningstar
Aug 1, 2024 ImmuneOnco will receive an upfront payment and potential near-term payments of up to $50 million as well as potential additional development, regulatory, and commercial โฆSee details»
Instil refills pipeline in $2B biobucks deal with ImmunOnco
Aug 1, 2024 The deal terms mean Instil will gain the rights to both candidates everywhere outside of greater China. On top of the combined $2.05 billion in biobucks up for grabs, โฆSee details»
Instil Bio and ImmuneOnco Announce License and - GlobeNewswire
Aug 1, 2024 ImmuneOnco is a clinical-stage biotech company focused on discovery and development of biologics to treat cancers and other diseases. With 10+ assets all originated in โฆSee details»
ImmuneOnco Advances Cancer Drug Trials with Promising Results
Nov 13, 2024 ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.ImmuneOnco Biopharmaceuticals has initiated a Phase II clinical trial for its drug โฆSee details»
Instil Bio and ImmuneOnco Announce Global Registrational โฆ
Sep 16, 2024 In China, ImmuneOnco is accelerating the development of IMM2510/SYN-2510 in front-line NSCLC by targeting initiation in late 2024 of a Phase 1b/2 front-line chemo โฆSee details»
Phase II clinical trial of Immune Onco IMM01 combined with PD-1 ...
On January 20, 2023, ImmuneOnco Biomedical Technology (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that the first domestic SIRPฮฑFc fusion protein drug โฆSee details»
Week In Review: ImmuneOnco Out-Licenses 2 Antibodies In $2 โฆ
Aug 4, 2024 ImmuneOnco will receive an upfront and near-term payments of $50 million and up to more than $2 billion in milestones, plus royalties. Instil will have rights to ImmuneOncoโs โฆSee details»